Eli Lilly’s Alzheimer’s Drug Donanemab Is Being Considered For FDA Approval—Here’s What To Know

Forbes June 10, 2024
Robert Hart

Topline

A panel of experts advising the Food and Drug Administration could on Monday recommend Eli Lilly’s experimental Alzheimer’s drug donanemab for FDA approval, a closely watched decision that could pave the way for the drug to become the second of its kind authorized in the U.S.

Key Facts

What To Watch For

The FDA is not required to follow the recommendations of its expert panels but it does put significant weight in their opinions. It is not clear when the FDA may make a final decision or how long it would take Lilly to roll out the treatment once approved. At least two analysts told Reuters they expect the FDA to eventually approve Lilly’s drug. If approved, the agency...

Today's Sponsors

Today's Sponsor